Physician profile
Katherine E Barrett
NPI 1275500779
$3,808.14
in general payments reported to CMS, 2019-2025
36 companies · $618 in 2025
The $618 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $220 · 2021: $277 · 2022: $626 · 2023: $804 · 2024: $736 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.24 |
| Education | $181.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $710.90 | 2022-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $662.95 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $411.01 | 2019-2025 | |
| Pfizer INC. | $256.52 | 2019-2025 | |
| Abbvie INC. | $216.12 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Evofem Biosciences, INC. | $181.80 | 2021-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $162.78 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Organon LLC | $135.44 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $108.81 | 2019-2025 | Paragard T 380a, Endosee |
| Therapeuticsmd, INC. | $92.43 | 2019-2021 | |
| Shield Therapeutics INC | $85.31 | 2023-2025 | Accrufer |
| Myriad Women'S Health, INC. | $69.73 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $66.37 | 2023-2025 | Myfembree, Gemtesa |
| Daiichi Sankyo INC. | $50.42 | 2019-2021 | |
| Avion Pharmaceuticals | $43.73 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $40.70 | 2019-2021 | |
| Minerva Surgical, INC | $40.28 | 2019 | |
| Allergan, INC. | $38.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.40 | 2020 | |
| Aspira Women'S Health INC | $36.86 | 2021-2024 | Ova1 |
| Myovant Sciences INC. | $36.42 | 2021 | |
| Duchesnay USA Incorporated | $32.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $29.75 | 2019 | |
| Biogen, INC. | $26.66 | 2025 | Zurzuvae |
| Amgen INC. | $26.23 | 2019 | |
| Amag Pharmaceuticals, INC. | $25.46 | 2019 | |
| Scynexis, INC. | $24.95 | 2022 | |
| Sage Therapeutics, LLC | $23.52 | 2023 | |
| Agile Therapeutics, INC. | $22.38 | 2021 | |
| Astellas Pharma Global Development | $22.15 | 2024 | Veozah |
| Vertex Pharmaceuticals Incorporated | $21.77 | 2025 | |
| Vertical Pharmaceuticals, LLC | $19.80 | 2019 | |
| Smith+Nephew, INC. | $16.59 | 2019 | |
| Exeltis, USA INC. | $16.37 | 2020 | |
| Exact Sciences Corporation | $16.34 | 2023 | Cologuard Collection Kit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.